datetime,headline,summary,related,lang,source
2020-10-20 20:10:44-05:00,Saul Centers (NYSE:BFS) Lowered to Sell at Zacks Investment Research,"Zacks Investment Research downgraded shares of Saul Centers (NYSE:BFS) from a hold rating to a sell rating in a research report released on Tuesday, Zacks.com reports. According to Zacks, “SAUL CENTERS, INC. is a real estate investment trust which is engaged in the management and development of the shopping center business of the Saul Organization. […]",BFS,en,Daily Political
2020-10-20 01:03:11-05:00,Saul Centers (NYSE:BFS) Cut to “Strong Sell” at ValuEngine,"ValuEngine lowered shares of Saul Centers (NYSE:BFS) from a sell rating to a strong sell rating in a research report report published on Saturday morning, ValuEngine reports. BFS has been the subject of several other research reports. DA Davidson reissued a neutral rating on shares of Saul Centers in a report on Monday, August 10th. […]",BFS,en,Transcript Daily
2020-05-06 18:25:06-05:00,Saul Centers (BFS) Q1 FFO Surpass Estimates,"Saul Centers (BFS) delivered FFO and revenue surprises of 1.25% and -1.72%, respectively, for the quarter ended March 2020. Do the numbers hold clues to what lies ahead for the stock?",BFS,en,Zacks Investment Research
2019-11-08 08:14:09-05:00,"The Daily Biotech Pulse: Therapix Calls Off Merger, Alimera's Reverse Split, 2 Biotechs To Debut","The following is a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech stocks that hit 52-week highs Nov. 7.) Collegium Pharmaceutical Inc (NASDAQ: COLL ) (reacted to third-quarter results released after the market close Wednesday) Deciphera Pharmaceuticals Inc (NASDAQ: DCPH ) DexCom, Inc. (NASDAQ: DXCM ) (reacted to its better-than-expected third-quarter results ) INNATE PHARMA S/S ADR (NASDAQ: IPHA ) Rapt Therapeutics Inc (NASDAQ: RAPT ) (went public Oct. 31) Viela Bio Inc (NASDAQ: VIE ) (went public Oct. 3) XOMA Corp (NASDAQ: XOMA ) Down In The Dumps (Biotech stocks that hit 52-week lows Nov. 7.) Allena Pharmaceuticals Inc (NASDAQ: ALNA ) (reported positive results from two studies evaluating its reloxaliase in high-risk patients with enteric hyperoxaluria and advanced chronic kidney disease) Auris Medical Holding Ltd (NASDAQ: EARS ) bluebird bio Inc (NASDAQ: BLUE ) Caladrius Biosciences Inc (NASDAQ: CLBS ) (reacted to its third-quarter results) CENTOGENE ORD (NASDAQ: CNTG ) (went public Thursday) Cocrystal Pharma Inc (NASDAQ: COCP ) Corbus Pharmaceuticals Holdings Inc (NASDAQ: CRBP ) Helius Medical Technologies Inc (NASDAQ: HSDT ) Infinity Pharmaceuticals Inc.",BFS,en,Benzinga
2019-11-07 05:38:02-05:00,"The Daily Biotech Pulse: Obseva Sinks On Adverse Clinical Readout, BioNano Surges On Saphyr Adoption, 2 IPOs","Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks hitting 52-week highs on Nov. 6) Agile Therapeutics Inc (NASDAQ: AGRX )(follow-on rally following positive Adcom verdict for Twirla) Constellation Pharmaceuticals Inc (NASDAQ: CNST )(announced positive results from a Phase 2 trial of CPI-0610 in combination with Jakafi in myelofibrosis) Exagen Inc (NASDAQ: XGN ) INNATE PHARMA S/S ADR (NASDAQ: IPHA ) Momenta Pharmaceuticals, Inc. (NASDAQ: MNTA ) Repro-Med Systems, Inc. (NASDAQ: KRMD ) TFF Pharmaceuticals Inc (NASDAQ: TFFP ) Viela Bio Inc (NASDAQ: VIE ) (IPOed Oct. 3) ZEALAND PHARMA/S ADR (NASDAQ: ZEAL ) Down In The Dumps (Biotech stocks hitting 52-week lows on Nov. 6) AcelRx Pharmaceuticals Inc (NASDAQ: ACRX ) Achieve Life Sciences Inc (NASDAQ: ACHV ) AVEO Pharmaceuticals, Inc. (NASDAQ: AVEO ) Biocept Inc (NASDAQ: BIOC ) bluebird bio Inc (NASDAQ: BLUE ) Cocrystal Pharma Inc (NASDAQ: COCP ) Corbus Pharmaceuticals Holdings Inc (NASDAQ: CRBP ) Cyclerion Therapeutics Inc (NASDAQ: CYCN ) Diffusion Pharmaceuticals Inc (NASDAQ: DFFN ) Exelixis, Inc.","BIOC,BFS",en,Benzinga
2019-10-25 06:12:03-05:00,"The Daily Biotech Pulse: Melinta Crosses FDA Hurdle But Sees Liquidity Pushback, Positive Readout For Aclaris Wart Drug","Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks hitting 52-week highs on Oct. 24) AstraZeneca plc (NYSE: AZN ) (reacted to a beat-and-raise quarter) Edwards Lifesciences Corp (NYSE: EW )( reported better-than-expected third-quarter results) Frequency Therapeutics Inc (NASDAQ: FREQ ) (IPOed Oct. 3) GlaxoSmithKline plc (NYSE: GSK )(FDA approved expanded use of Zejula) Novo Nordisk A/S (NYSE: NVO ) Down In The Dumps (Biotech stocks hitting 52-week lows on Oct. 24) Acorda Therapeutics Inc NASDAQ: ACOR) (announced restructuring plan, including the elimination of 25% of its workforce) Adaptimmune Therapeutics PLC – ADR (NASDAQ: ADAP ) bluebird bio Inc (NASDAQ: BLUE ) (announced resignation of chief strategy officer) Brickell Biotech Inc (NASDAQ: BBI ) CytomX Therapeutics Inc (NASDAQ: CTMX ) Diffusion Pharmaceuticals Inc (NASDAQ: DFFN ) Gritstone Oncology Inc (NASDAQ: GRTS ) KemPharm Inc (NASDAQ: KMPH ) MacroGenics Inc (NASDAQ: MGNX ) Midatech Pharma PLC-ADR (NASDAQ: MTP ) OpGen Inc (NASDAQ: OPGN ) )(announcing pricing of previously-announced underwritten common stock offering) Opko Health Inc. (NASDAQ: OPK )(announced a follow-on offering) Orgenesis Inc (NASDAQ: ORGS ) Rexahn Pharmaceuticals, Inc. (NASDAQ: REXN ) Titan Medical Inc. (NASDAQ: TMDI ) Stocks In Focus Melinta Gets FDA Nod For Baxdela Label Expansion; Launch to Be Delayed Due to Liquidity Concerns Melinta Therapeutics Inc (NASDAQ: MLNT ) announced FDA approval for Baxdela for the treatment of adult patients with community-acquired bacterial pneumonia, or CABP, caused by designated succeptible bacteria.",BFS,en,Benzinga
2019-10-04 06:32:50-05:00,"The Daily Biotech Pulse: Arbutus Halts Hepatitis B Study, Positive Readout For MEI Pharma's Blood Cancer Drug, Ovid Offering","Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks hitting 52-week lows on Oct. 3) Aprea Therapeutics Inc (NASDAQ: APRE ) (IPOed on Thursday) Viela Bio Incn (NASDAQ: VIE ) (IPOed on Thursday) Down In The Dumps (Biotech stocks hitting 52-week lows on Oct. 3) Adamas Pharmaceuticals Inc (NASDAQ: ADMS ) Adaptimmune Therapeutics PLC – ADR (NASDAQ: ADAP ) Alpine Immune Sciences Inc (NASDAQ: ALPN ) bluebird bio Inc . (NASDAQ: BLUE ) Corvus Pharmaceuticals Inc (NASDAQ: CRVS ) DelMar Pharmaceuticals Inc (NASDAQ: DMP ) Eloxx Pharmaceuticals Inc (NASDAQ: ELOX ) Erytech Pharma SA (NASDAQ: ERYP ) Frequency Therapeutics Inc (NASDAQ: FREQ )(IPOed on Thursday) Fulcrum Therapeutics Inc (NASDAQ: FULC ) Jaguar Health Inc (NASDAQ: JAGX ) Karuna Therapeutics Inc (NASDAQ: KRTX ) Kiniksa Pharmaceuticals Ltd (NASDAQ: KNSA ) Madrigal Pharmaceuticals Inc (NASDAQ: MDGL ) Neuralstem, Inc. (NASDAQ: CUR ) Obseva SA (NASDAQ: OBSV ) Onconova Therapeutics Inc (NASDAQ: ONTX ) RA Medical Systems Inc (NYSE: RMED ) Sierra Oncology Inc (NASDAQ: SRRA ) Titan Pharmaceuticals, Inc. (NASDAQ: TTNP ) Trinity Biotech plc (NASDAQ: TRIB ) Viveve Medical Inc (NASDAQ: VIVE ) Stocks In Focus Arbutus Halts Hepatitis B Drug Study Arbutus Biopharma Corp (NASDAQ: ABUS ) decided to discontinue the development of AB-506, an oral capsid inhibitor, which was being evaluated in a Phase 1a/1b trial for the treatment …",BFS,en,Benzinga
2019-08-07 17:35:06-05:00,Saul Centers (BFS) Tops Q2 FFO Estimates,"Saul Centers (BFS) delivered FFO and revenue surprises of 1.23% and -0.44%, respectively, for the quarter ended June 2019. Do the numbers hold clues to what lies ahead for the stock?",BFS,en,Zacks Investment Research
2019-08-01 09:09:00-05:00,"REITs to Watch for Q2 Earnings on Aug 2: WPC, CHSP & BFS","Let's delve into the factors that will likely impact Q2 performance of W. P. Carey (WPC), Chesapeake Lodging (CHSP) and Saul Centers (BFS).",BFS,en,Zacks Investment Research
2019-05-02 19:35:06-05:00,Saul Centers (BFS) Tops Q1 FFO and Revenue Estimates,"Saul Centers (BFS) delivered FFO and revenue surprises of 3.70% and 2.65%, respectively, for the quarter ended March 2019. Do the numbers hold clues to what lies ahead for the stock?",BFS,en,Zacks Investment Research
2019-05-02 16:00:37-05:00,"Saul Centers beats by $0.03, beats on revenue",No summary available.,BFS,en,Seeking Alpha
2019-05-02 15:08:00-05:00,"Saul Centers, Inc. Reports First Quarter 2019 Earnings","BETHESDA, Md. , May 2, 2019 /PRNewswire/ -- Saul Centers , Inc. (NYSE: BFS ), an equity real estate investment trust (""REIT""), announced its operating results for the quarter ended March 31, 2019 (""2019 Quarter""). Total revenue for the 2019 Quarter increased to $59.8 million from $56 .1 million for the quarter ended March 31, 2018 (""2018 Quarter""). Net income increased to $17 .1 million for the 2019 Quarter from $14.9 million for the 2018 Quarter. Net income available to common stockholders increased to $10 .5 million ( $0.46 per diluted share) for the 2019 Quarter from $6.9 million ( $0.31 per diluted share) for the 2018 Quarter. Net income available to common stockholders increased primarily due to (a) extinguishment in 2018 of issuance costs upon redemption of preferred shares ( $2.3 million ), (b) higher termination fees in the core portfolio ( $1 .2 million), (c) the net operating income of recently acquired properties ( $0.6 million ), (d) lower preferred stock dividends ( $0.5 million ) and (e) higher base rent in the core portfolio ( $0.5 million ) partially offset by (f) higher noncontrolling interests ( $1.3 million ).",BFS,en,Benzinga
